Mikhail Blagosklonny is among the scientists leading the fight against cancer and aging. He is one of the most vocal researchers in the field, and his life-long research is showing promise of a solution to two of the world’s biggest health challenges.
Here is a brief overview of the career of one of oncology’s most dedicated researchers.
Education and Occupation
Mikhail Blagosklonny acquired his knowledge from one of the best institutes in the country: Pavlov State Medical University of St. Petersburg. He first acquired his M.D. in Internal Medicine and later a PhD in Experimental Medicine. However, his education did not end there as he is continually researching and studying and editing other researchers’ reports.
His career started in 2002 shortly after his graduation. He first worked for the New York Medical College where he was appointed as an associate professor of medicine. He was later appointed as a senior scientist at Ordway Research Institute where he worked until 2009.
Mikhail Blagosklonny currently works at the Roswell Park Cancer Institute based in Buffalo, New York. He is both a professor and senior scientist who pioneers research on oncology and aging. The institute is the only one in New York to bear the designation of Comprehensive Cancer Center awarded by the National Cancer Institute. It was also the first medical facility dedicated for cancer treatment and research in the U.S., and it has been operational since 1898. View his LinkedIn profile to know more about Mikhail
For years now, Mikhail Blagosklonny has been leading a research on the potential manipulation of Target of Rapamycin (TOR) for battling cancer and aging. Here are his findings thus far.
Explaining Target of Rapamycin
Target of Rapamycin pathways control and coordinate development, growth, and aging. They are affected by a host of external and internal factors including nutritional intake, body exercise, and psychological stress, among others.
Mikhail Blagosklonny believes that TOR pathways can be manipulated which would, in turn, allow the control and coordination of growth, development, and aging. Cancer and aging are directly associated to growth, and success of this theory would be a major breakthrough in their treatment. Besides, TOR signaling is considered to be safer and more effective than existing medications.